Last updated on January 2010

Migraine Study for Men or Women ages 18 to 65 Currently Using Triptans. (e.g., Almotriptan/Axert; Frovatriptan/Frova; Rizatriptan/Maxalt; Sumatriptan/Imitrex; Zolmitriptan/Zomig)


Brief description of study

Migraine Study for Men or Women ages 18 to 65 Currently Using Triptans. (e.g., Almotriptan/Axert; Frovatriptan/Frova; Rizatriptan/Maxalt; Sumatriptan/Imitrex; Zolmitriptan/Zomig)

Detailed Study Description

A Multicenter, Open-Label Evaluation of Treatment Satisfaction, Tolerability, Safety, and Preference of Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated with Triptans

Patient Inclusion Criteria:

  • Men or Women 18 to 65 years of age
  • Have a history of 2 to 6 migraine headaches (on average) per month
  • Suffering from Migraines for more than one (1) year before first office visit
  • Willing to stop or discontinue current treatment for Migraines Headaches
  • Diagnosis of Migraine Headaches before the age of 50
  • Be Fluent in English

Patient Exclusion Criteria:

  • Can not read or understand English Forms
  • History of Epilepsy or Seizure or any other Neurologic Condition
  • HIV/AIDS, Cancer or Hepatitis C (detectable or undetectable)
  • Hemiplegic or Basilar Migraines
  • Terminal Illnesses
  • Uncontrolled Cardiovascular Diseases (Uncontrolled Hypertension)
  • Minors (under the legal age of 18)
  • Older than the permitted age of 65

Clinical Study Identifier: TX134653

Contact Investigators or Research Sites near you

Start Over

Diana

University Clinical Research, Inc.
Pembroke Pines, FL USA
  Connect »